Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1826
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 1141–1152 of 1,826 matching trials with a site at Mayo Clinic, Rochester, MN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology

NCT05184569
Site status not listed — check the official record
View directory record Official record
Conditions
Semantic Dementia
Interventions
Verdiperstat
Drug
Lead sponsor
Peter Ljubenkov, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Recruiting No phase listed Observational

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

NCT01351545
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Hematologic Malignancies, Inherited Disorders of Metabolism, Inherited Abnormalities of Platelets, Histiocytic Disorders, Acute Myelogenous Leukemia (AML or ANLL), Acute Lymphoblastic Leukemia (ALL), Other Acute Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Other Leukemia, Hodgkin Lymphoma, Non-hodgkin Lymphoma, Multiple Myeloma/ Plasma Cell Disorder (PCD), Inherited Abnormalities of Erythrocyte Differentiation or Function, Disorders of the Immune System, Autoimmune Diseases, Severe Aplastic Anemia
Interventions
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
Drug
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
Not listed
Enrollment
99,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2041
U.S. locations
142
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Screening for High Frequency Malignant Disease

NCT05117840
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Cancer
Interventions
Low-dose CT scan
Device
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
12,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
125
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Anaheim, California + 105 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Active, not recruiting Phase 2 Interventional

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

NCT07033481
Site status not listed — check the official record
View directory record Official record
Conditions
Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
Interventions
Neflamapimod, Placebo
Drug
Lead sponsor
EIP Pharma Inc
Industry
Eligibility
40 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
5
States / cities
Chicago, Illinois • Rochester, Minnesota • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Active, not recruiting Early Phase 1 Interventional

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

NCT03573349
Site status not listed — check the official record
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression, Bipolar Depression
Interventions
Ketamine
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Recruiting No phase listed Observational

Localized Leiomyosarcoma Biomarker Protocol

NCT04925089
Status at this site: Recruiting
View directory record Official record
Conditions
Leiomyosarcoma
Interventions
Blood and Tissue collection
Other
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Ann Arbor, Michigan • Rochester, Minnesota • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Recruiting Not applicable Interventional

Virtual Group Resilient Living Program For Patients Living With Advanced Cancer

NCT07659158
Status at this site: Recruiting
View directory record Official record
Conditions
Advanced Cancer
Interventions
Virtual Group Resilient Living Program (RLP), Survey Completion
Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Recruiting No phase listed Observational

Hairy Cell Leukemia Patient Data Registry

NCT02560883
Status at this site: Recruiting
View directory record Official record
Conditions
Leukemia, Other
Interventions
Not listed
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2030
U.S. locations
5
States / cities
Miami, Florida • Miami Beach, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Active, not recruiting Phase 3 Interventional

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)

NCT02193282
Site status not listed — check the official record
View directory record Official record
Conditions
Lung Non-Squamous Non-Small Cell Carcinoma, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Interventions
Clinical Observation, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Placebo Administration
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1403
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 888 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Active, not recruiting Phase 3 Interventional

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

NCT06578247
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia
Interventions
Quizartinib, Placebo, Chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
52
States / cities
Goodyear, Arizona • Phoenix, Arizona • Tucson, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Active, not recruiting Phase 2 Interventional

A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have

NCT05831176
Site status not listed — check the official record
View directory record Official record
Conditions
Eosinophilic Gastritis (EoG), Eosinophilic Duodenitis (EoD), Eosinophilic Gastrointestinal Disease (EGID), Eosinophilic Gastroenteritis
Interventions
Dupilumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
36
States / cities
Phoenix, Arizona • Apple Valley, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 15, 2026, 2:43 AM EST
Active, not recruiting Phase 1 Interventional

Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis

NCT05802056
Site status not listed — check the official record
View directory record Official record
Conditions
Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum
Interventions
Aldesleukin, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Diagnostic Laparoscopy, Fluorouracil, Leucovorin Calcium, Magnetic Resonance Imaging, Nivolumab, Oxaliplatin, Positron Emission Tomography
Biological · Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Nov 15, 2026, 2:43 AM EST

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.